8-K: Sensus Healthcare Q2 2025: Revenue Falls, Net Loss Widens

Sensus Healthcare reported a net loss of $1.0 million on revenues of $7.3 million for Q2 2025, impacted by lower unit sales and proposed reimbursement changes.

Summary

• Revenues for the second quarter of 2025 were $7.3 million, a decrease from $9.2 million in the prior-year quarter.
• The company reported a net loss of $1.0 million, or $0.06 per share, for Q2 2025, compared to net income of $1.6 million, or $0.10 per diluted share, in Q2 2024.
• Sensus Healthcare shipped 19 superficial radiotherapy (SRT) systems during the quarter, including four to China.
• Five new Fair Deal Agreements (FDAs) were signed, with four going live during the quarter, contributing to a 27% sequential-quarter increase in FDA treatment volume.
• Adjusted EBITDA for Q2 2025 was negative $1.8 million, a significant decline from positive $2.1 million in Q2 2024.
• Gross margin decreased to 39.7% in Q2 2025 from 58.7% in Q2 2024, primarily due to lower sales and higher cost of service.
• The company exited the quarter with $22.2 million in cash and no debt.
• For the first half of 2025, revenues were $15.7 million (down from $19.9 million in H1 2024) and net loss was $3.6 million (compared to net income of $3.9 million in H1 2024).

Sentiment

Score: 3

Explanation: While there are strategic positives like MDSAP certification and the ROS partnership, and a potentially favorable future reimbursement change, the immediate financial results (revenue decline, net loss, negative EBITDA, gross margin contraction) and the impact of current reimbursement uncertainty are significant negatives. The future positive impact is contingent and not immediate.

Positives

• FDA treatment volume increased 27% sequentially over the first quarter, indicating gaining traction for the FDA model.
• Received MDSAP certification for the full SRT product portfolio, supporting global regulatory access and commercial expansion.
• Engaged Radiology Oncology Systems (ROS) as a primary distribution partner to hospital-based radiation oncology departments and freestanding oncology centers nationwide, expanding market reach.
• Exited the quarter with a strong cash position of $22.2 million and no debt.
• A proposed Medicare Physician Fee Schedule, open for comments through mid-September and effective January 1, 2026, is expected to favorably impact the adoption of SRT technology by aligning outpatient SRT payments with higher hospital rates.

Negatives

• Revenues decreased to $7.3 million in Q2 2025 from $9.2 million in Q2 2024, primarily due to lower unit sales to a large customer.
• Reported a net loss of $1.0 million in Q2 2025, a significant reversal from net income of $1.6 million in Q2 2024.
• Adjusted EBITDA was negative $1.8 million in Q2 2025, compared to positive $2.1 million in Q2 2024.
• Gross margin declined substantially to 39.7% in Q2 2025 from 58.7% in Q2 2024, driven by lower sales and higher cost of service.
• Domestic sales momentum was impacted by a proposed Local Coverage Determination (LCD) to limit reimbursement for ultrasound when used with the SRT-100 Vision, which became public in mid-May.
• Operating expenses increased across general and administrative, selling and marketing, and research and development categories.

Risks

• The possibility that inflationary pressures continue to impact sales.
• The level and availability of government and/or third-party payor reimbursement for clinical procedures using products, and the willingness of healthcare providers to purchase products if reimbursement declines.
• Concentration of customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.
• The development by others of new products, treatments, or technologies that render Sensus's technology partially or wholly obsolete.
• Regulatory requirements applicable to Sensus and its competitors.
• Ability to efficiently manage manufacturing processes and costs.
• Risks arising from doing business in China and other foreign countries.
• Legislation, regulation, or other governmental action that affects products, taxes, international trade regulation (including the possibility of tariffs).
• The performance of the company's information technology systems and its ability to maintain data security.
• Ability to obtain and maintain the intellectual property needed to adequately protect products, and ability to avoid infringing or otherwise violating the intellectual property rights of third parties.

Future Outlook

Management anticipates that the recently announced partnership with Radiology Oncology Systems (ROS) will begin to yield tangible results later this year. Furthermore, the proposed Medicare Physician Fee Schedule, if finalized, is expected to favorably impact the adoption of SRT technology beginning January 1, 2026, by aligning outpatient SRT payments with higher hospital rates.

Management Comments

• "Our financial performance was tracking ahead of expectations throughout the first half of the quarter, yet domestic sales momentum was impacted by a proposed Local Coverage Determination (LCD) to limit the reimbursement for ultrasound when used with our SRT-100 Vision that became public in mid-May." Joe Sardano, Chairman and Chief Executive Officer.
• "As importantly, in July Medicare proposed a Physician Fee Schedule to align outpatient SRT payments with the higher hospital rates. This schedule is open to comments through mid-September and if finalized, will be effective as of January 1, 2026." Joe Sardano.
• "Against this dynamic reimbursement landscape, the Sensus team executed very well across our strategic priorities and continued to advance key commercial and operational initiatives, including expanding our international presence, growing our FDA base and unlocking new global opportunities through MDSAP certification." Joe Sardano.
• "We shipped 19 SRT systems during the quarter, including four to China, signed five additional FDA contracts and activated four sites. Importantly, FDA treatment volume increased 27% sequentially vs Q1. Based on these trends, we believe our FDA model is gaining traction and delivering value to both Sensus and our customers." Joe Sardano.
• "Our recently announced partnership with ROS to serve as our primary distribution partner to hospital systems and radiation oncology departments represents an important commercial milestone... This agreement builds upon our strong base in dermatology and supports broader adoption of SRT in complementary care settings. We anticipate this relationship will begin to yield tangible results later this year." Joe Sardano.

Industry Context

The medical device industry, particularly in oncology and dermatology, is heavily influenced by reimbursement policies. Sensus Healthcare's focus on expanding its distribution channels to hospital systems and radiation oncology departments, beyond its traditional dermatology base, aligns with a broader trend of seeking diversified market penetration. The proposed changes in Medicare's Physician Fee Schedule highlight the ongoing regulatory scrutiny and potential for significant shifts in market dynamics for medical technologies, emphasizing the importance of favorable reimbursement for product adoption.

Stakeholder Impact

• Shareholders: Negative impact due to the reported net loss, revenue decline, and negative Adjusted EBITDA. Potential for future positive impact from strategic initiatives and favorable reimbursement changes.
• Customers (Healthcare Providers): Uncertainty regarding reimbursement policies (LCD and proposed Physician Fee Schedule) could affect purchasing decisions. The new distribution partnership with ROS aims to expand access and support broader adoption.
• Employees: Increased headcount in selling and marketing, and R&D, suggests continued investment in personnel despite the financial downturn.
• Suppliers: No direct impact mentioned, but lower unit sales could indirectly affect demand for components or services.

Next Steps

• Sensus Healthcare will host an investment community conference call on August 7, 2025, at 4:30 p.m. Eastern time.
• The proposed Medicare Physician Fee Schedule is open to comments through mid-September.
• The partnership with Radiology Oncology Systems (ROS) is anticipated to begin yielding tangible results later this year.
• If finalized, the proposed Medicare Physician Fee Schedule will be effective as of January 1, 2026.

Key Dates

Recommendation

The company reported significantly weaker financial results for Q2 2025, including a revenue decline, net loss, and negative Adjusted EBITDA, which are concerning. However, there are strategic initiatives (MDSAP certification, ROS partnership) and a potentially favorable future reimbursement change (Physician Fee Schedule effective January 1, 2026) that could improve performance in the long term. The current quarter's performance was also impacted by a proposed LCD, indicating external factors. Given the mixed signals – poor current performance but potential future catalysts – a 'hold' recommendation is appropriate to observe how these strategic and regulatory developments unfold.

Keywords

Sensus Healthcare, SRTS, medical device, superficial radiotherapy, SRT, skin cancer, keloids, financial results, Q2 2025, revenue, net loss, FDA, reimbursement, MDSAP, Radiology Oncology Systems, oncology, dermatology